# A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

> **NCT06799026** · PHASE1 · RECRUITING · sponsor: **David Avigan** · enrollment: 25 (estimated)

## Conditions studied

- Multiple Myeloma
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab
- **BIOLOGICAL:** GM-CSF
- **BIOLOGICAL:** DC/MM Fusion Vaccine

## Key facts

- **NCT ID:** NCT06799026
- **Lead sponsor:** David Avigan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2028-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06799026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06799026, "A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06799026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*